 Christopher Lieu
Concepts (366)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 41 | 2023 | 621 | 8.480 |
Why?
| | Molecular Targeted Therapy | 9 | 2019 | 347 | 2.140 |
Why?
| | Antineoplastic Agents | 14 | 2021 | 1895 | 2.120 |
Why?
| | Biomarkers, Tumor | 16 | 2023 | 1053 | 2.060 |
Why?
| | Colonic Neoplasms | 7 | 2023 | 221 | 2.030 |
Why?
| | Rectal Neoplasms | 7 | 2023 | 121 | 1.850 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 16 | 2023 | 1361 | 1.510 |
Why?
| | Neoplasms | 12 | 2022 | 2105 | 1.310 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2019 | 642 | 1.140 |
Why?
| | Immunotherapy | 4 | 2022 | 475 | 1.010 |
Why?
| | Mutation | 12 | 2020 | 3349 | 0.950 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2020 | 498 | 0.920 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 4 | 2019 | 229 | 0.870 |
Why?
| | Oncologists | 1 | 2023 | 31 | 0.870 |
Why?
| | Cetuximab | 4 | 2023 | 91 | 0.860 |
Why?
| | Bevacizumab | 4 | 2020 | 115 | 0.850 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2023 | 59 | 0.830 |
Why?
| | Antibodies, Monoclonal | 6 | 2023 | 1270 | 0.800 |
Why?
| | Microsatellite Instability | 6 | 2022 | 32 | 0.750 |
Why?
| | Neuroendocrine Tumors | 5 | 2022 | 85 | 0.740 |
Why?
| | Neoplasm Staging | 11 | 2023 | 1176 | 0.720 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2020 | 664 | 0.710 |
Why?
| | Age of Onset | 7 | 2022 | 447 | 0.680 |
Why?
| | Humans | 82 | 2023 | 114716 | 0.660 |
Why?
| | Piperidines | 2 | 2017 | 161 | 0.640 |
Why?
| | Early Detection of Cancer | 2 | 2022 | 328 | 0.620 |
Why?
| | Colectomy | 1 | 2019 | 86 | 0.620 |
Why?
| | Cyclosporine | 1 | 2018 | 161 | 0.590 |
Why?
| | Terminology as Topic | 1 | 2019 | 187 | 0.580 |
Why?
| | Genetic Predisposition to Disease | 4 | 2022 | 2099 | 0.580 |
Why?
| | Pancreatic Neoplasms | 6 | 2023 | 732 | 0.580 |
Why?
| | Disease-Free Survival | 7 | 2023 | 623 | 0.580 |
Why?
| | Benzimidazoles | 1 | 2018 | 138 | 0.570 |
Why?
| | Azetidines | 1 | 2017 | 31 | 0.570 |
Why?
| | Appendiceal Neoplasms | 2 | 2020 | 14 | 0.550 |
Why?
| | Medical Oncology | 5 | 2023 | 229 | 0.530 |
Why?
| | Healthcare Disparities | 1 | 2021 | 479 | 0.520 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2022 | 81 | 0.500 |
Why?
| | Precision Medicine | 1 | 2019 | 338 | 0.500 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2015 | 68 | 0.500 |
Why?
| | Patient Rights | 1 | 2015 | 10 | 0.490 |
Why?
| | Pyrimidinones | 1 | 2015 | 88 | 0.490 |
Why?
| | Therapies, Investigational | 1 | 2015 | 14 | 0.490 |
Why?
| | Drug and Narcotic Control | 1 | 2015 | 29 | 0.490 |
Why?
| | Drugs, Investigational | 1 | 2015 | 30 | 0.480 |
Why?
| | Pyridones | 1 | 2015 | 123 | 0.470 |
Why?
| | Neovascularization, Pathologic | 2 | 2013 | 283 | 0.470 |
Why?
| | Adenocarcinoma | 5 | 2023 | 801 | 0.470 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 147 | 0.450 |
Why?
| | Pyrazines | 2 | 2018 | 71 | 0.450 |
Why?
| | Middle Aged | 30 | 2022 | 26746 | 0.430 |
Why?
| | Immunoglobulin G | 1 | 2017 | 774 | 0.430 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 165 | 0.420 |
Why?
| | Proto-Oncogene Proteins B-raf | 4 | 2020 | 193 | 0.420 |
Why?
| | Drug Design | 1 | 2013 | 151 | 0.410 |
Why?
| | Neoadjuvant Therapy | 5 | 2023 | 305 | 0.410 |
Why?
| | ErbB Receptors | 5 | 2017 | 560 | 0.410 |
Why?
| | Neoplasm Metastasis | 7 | 2022 | 528 | 0.400 |
Why?
| | Terminal Care | 1 | 2015 | 213 | 0.390 |
Why?
| | Carcinoma, Signet Ring Cell | 1 | 2011 | 3 | 0.380 |
Why?
| | Circulating Tumor DNA | 2 | 2022 | 23 | 0.380 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2013 | 312 | 0.380 |
Why?
| | Aged | 23 | 2022 | 19079 | 0.360 |
Why?
| | Adult | 27 | 2022 | 30543 | 0.360 |
Why?
| | Fibroblast Growth Factors | 1 | 2011 | 162 | 0.350 |
Why?
| | src-Family Kinases | 1 | 2010 | 88 | 0.330 |
Why?
| | Stomach Neoplasms | 3 | 2022 | 65 | 0.330 |
Why?
| | Patient Selection | 3 | 2019 | 641 | 0.330 |
Why?
| | Health Services Accessibility | 1 | 2015 | 763 | 0.320 |
Why?
| | Disease Management | 4 | 2021 | 560 | 0.310 |
Why?
| | Fluorouracil | 4 | 2022 | 152 | 0.310 |
Why?
| | Male | 31 | 2022 | 55558 | 0.310 |
Why?
| | Boronic Acids | 1 | 2008 | 33 | 0.310 |
Why?
| | Janus Kinase 2 | 1 | 2008 | 31 | 0.300 |
Why?
| | Etoposide | 1 | 2008 | 148 | 0.300 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2021 | 706 | 0.300 |
Why?
| | Carboplatin | 1 | 2008 | 135 | 0.300 |
Why?
| | Myeloproliferative Disorders | 1 | 2008 | 26 | 0.300 |
Why?
| | Clinical Decision-Making | 3 | 2019 | 268 | 0.300 |
Why?
| | Genomics | 3 | 2022 | 639 | 0.300 |
Why?
| | Female | 31 | 2022 | 59486 | 0.290 |
Why?
| | Kaplan-Meier Estimate | 6 | 2017 | 815 | 0.290 |
Why?
| | Shock, Septic | 1 | 2009 | 185 | 0.280 |
Why?
| | Pathology, Clinical | 2 | 2017 | 32 | 0.280 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2023 | 333 | 0.280 |
Why?
| | Pathology, Molecular | 2 | 2017 | 26 | 0.280 |
Why?
| | Drug Administration Schedule | 4 | 2019 | 718 | 0.270 |
Why?
| | Clinical Trials as Topic | 3 | 2015 | 934 | 0.260 |
Why?
| | ras Proteins | 2 | 2017 | 138 | 0.260 |
Why?
| | Age Factors | 5 | 2021 | 2889 | 0.250 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1340 | 0.240 |
Why?
| | United States | 12 | 2021 | 12176 | 0.230 |
Why?
| | Signal Transduction | 6 | 2018 | 4521 | 0.220 |
Why?
| | Ovarian Neoplasms | 2 | 2020 | 388 | 0.220 |
Why?
| | Metastasectomy | 1 | 2023 | 13 | 0.220 |
Why?
| | Disease Models, Animal | 4 | 2021 | 3542 | 0.210 |
Why?
| | Clinical Trials, Phase II as Topic | 2 | 2022 | 59 | 0.210 |
Why?
| | Trifluridine | 1 | 2022 | 3 | 0.210 |
Why?
| | Camptothecin | 3 | 2022 | 98 | 0.210 |
Why?
| | Surgical Oncology | 1 | 2022 | 18 | 0.210 |
Why?
| | Genetic Testing | 3 | 2022 | 379 | 0.210 |
Why?
| | Survival Rate | 6 | 2023 | 1642 | 0.210 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2022 | 82 | 0.200 |
Why?
| | Membrane Proteins | 3 | 2019 | 1022 | 0.200 |
Why?
| | Microsatellite Repeats | 1 | 2022 | 136 | 0.200 |
Why?
| | Incidence | 6 | 2022 | 2312 | 0.200 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2023 | 40 | 0.190 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 30 | 0.190 |
Why?
| | Health Status Disparities | 2 | 2020 | 201 | 0.190 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2022 | 52 | 0.190 |
Why?
| | DNA | 1 | 2008 | 1351 | 0.190 |
Why?
| | Pheochromocytoma | 1 | 2022 | 54 | 0.190 |
Why?
| | Meningioma | 1 | 2022 | 77 | 0.180 |
Why?
| | Capecitabine | 2 | 2022 | 45 | 0.180 |
Why?
| | Practice Patterns, Physicians' | 1 | 2009 | 1178 | 0.180 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2023 | 212 | 0.180 |
Why?
| | Congresses as Topic | 2 | 2019 | 196 | 0.180 |
Why?
| | Heterografts | 1 | 2021 | 117 | 0.180 |
Why?
| | Treatment Outcome | 10 | 2021 | 9089 | 0.180 |
Why?
| | Consensus | 2 | 2019 | 535 | 0.170 |
Why?
| | Prognosis | 8 | 2023 | 3334 | 0.170 |
Why?
| | Immune System | 1 | 2021 | 173 | 0.170 |
Why?
| | Adenomatous Polyposis Coli Protein | 1 | 2019 | 18 | 0.170 |
Why?
| | Area Under Curve | 2 | 2018 | 275 | 0.170 |
Why?
| | Disease Progression | 4 | 2017 | 2384 | 0.160 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 447 | 0.160 |
Why?
| | Smad4 Protein | 1 | 2019 | 34 | 0.160 |
Why?
| | GTP Phosphohydrolases | 1 | 2019 | 66 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 1846 | 0.160 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 77 | 0.160 |
Why?
| | Retinal Vein | 1 | 2019 | 13 | 0.160 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2019 | 28 | 0.160 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 142 | 0.160 |
Why?
| | Young Adult | 4 | 2023 | 10462 | 0.160 |
Why?
| | Risk Factors | 6 | 2022 | 8626 | 0.160 |
Why?
| | Cohort Studies | 6 | 2020 | 4899 | 0.160 |
Why?
| | Neoplasm Grading | 1 | 2019 | 242 | 0.150 |
Why?
| | Vasculitis | 1 | 2019 | 70 | 0.150 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1080 | 0.150 |
Why?
| | Genes, ras | 1 | 2018 | 91 | 0.150 |
Why?
| | Drug Combinations | 2 | 2022 | 286 | 0.150 |
Why?
| | Retinal Diseases | 1 | 2019 | 76 | 0.150 |
Why?
| | Risk Assessment | 2 | 2019 | 2973 | 0.150 |
Why?
| | Survivorship | 1 | 2018 | 39 | 0.150 |
Why?
| | Population Surveillance | 1 | 2021 | 392 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 863 | 0.150 |
Why?
| | Neoplasm Transplantation | 1 | 2018 | 232 | 0.150 |
Why?
| | Patient Advocacy | 1 | 2018 | 66 | 0.150 |
Why?
| | Evidence-Based Medicine | 2 | 2019 | 667 | 0.150 |
Why?
| | Esophageal Neoplasms | 1 | 2021 | 273 | 0.150 |
Why?
| | Asthenia | 1 | 2017 | 1 | 0.150 |
Why?
| | Acneiform Eruptions | 1 | 2017 | 1 | 0.150 |
Why?
| | Patient Compliance | 1 | 2021 | 525 | 0.140 |
Why?
| | Aged, 80 and over | 7 | 2021 | 6346 | 0.140 |
Why?
| | Biomarkers | 3 | 2023 | 3414 | 0.140 |
Why?
| | Imidazoles | 1 | 2018 | 211 | 0.140 |
Why?
| | Drug Eruptions | 1 | 2017 | 26 | 0.140 |
Why?
| | Hypokalemia | 1 | 2017 | 24 | 0.140 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2019 | 198 | 0.140 |
Why?
| | Receptor, ErbB-3 | 1 | 2017 | 41 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 195 | 0.140 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2017 | 66 | 0.140 |
Why?
| | Retrospective Studies | 9 | 2023 | 12513 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 152 | 0.140 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2015 | 350 | 0.140 |
Why?
| | Time Factors | 2 | 2019 | 6124 | 0.140 |
Why?
| | Cell Line, Tumor | 3 | 2022 | 2725 | 0.140 |
Why?
| | Databases, Factual | 3 | 2017 | 1126 | 0.140 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2019 | 158 | 0.140 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 8 | 0.140 |
Why?
| | Hospitals | 1 | 2021 | 580 | 0.130 |
Why?
| | Animals | 9 | 2021 | 31761 | 0.130 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2018 | 286 | 0.130 |
Why?
| | Edema | 1 | 2016 | 118 | 0.130 |
Why?
| | Diabetic Neuropathies | 1 | 2016 | 79 | 0.130 |
Why?
| | Biliary Tract Neoplasms | 1 | 2015 | 20 | 0.130 |
Why?
| | GPI-Linked Proteins | 1 | 2016 | 54 | 0.130 |
Why?
| | Prevalence | 1 | 2022 | 2249 | 0.130 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2018 | 228 | 0.130 |
Why?
| | Patient Care Planning | 1 | 2016 | 139 | 0.130 |
Why?
| | Analgesics | 1 | 2016 | 158 | 0.120 |
Why?
| | Device Approval | 1 | 2015 | 21 | 0.120 |
Why?
| | Pancreas | 1 | 2017 | 277 | 0.120 |
Why?
| | Neuralgia | 1 | 2016 | 122 | 0.120 |
Why?
| | Leucovorin | 3 | 2022 | 43 | 0.120 |
Why?
| | Receptor, Notch1 | 1 | 2015 | 61 | 0.120 |
Why?
| | Immunoblotting | 1 | 2015 | 283 | 0.120 |
Why?
| | Health Behavior | 1 | 2020 | 704 | 0.120 |
Why?
| | Deoxycytidine | 1 | 2015 | 138 | 0.120 |
Why?
| | Administration, Oral | 1 | 2017 | 731 | 0.120 |
Why?
| | Immunoconjugates | 1 | 2016 | 87 | 0.120 |
Why?
| | Phenotype | 2 | 2021 | 2811 | 0.120 |
Why?
| | Gene Dosage | 1 | 2015 | 134 | 0.120 |
Why?
| | Drug Approval | 1 | 2015 | 78 | 0.120 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 158 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2018 | 206 | 0.120 |
Why?
| | Genetic Variation | 1 | 2019 | 876 | 0.120 |
Why?
| | Liver Neoplasms | 1 | 2018 | 507 | 0.120 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 172 | 0.120 |
Why?
| | Quinazolines | 1 | 2015 | 243 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2021 | 833 | 0.110 |
Why?
| | Spinal Cord Injuries | 1 | 2016 | 172 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1214 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 1 | 2017 | 610 | 0.110 |
Why?
| | beta Catenin | 1 | 2015 | 220 | 0.110 |
Why?
| | Registries | 1 | 2021 | 1759 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 743 | 0.110 |
Why?
| | Lymphocytes | 1 | 2015 | 332 | 0.110 |
Why?
| | Patient-Centered Care | 1 | 2018 | 474 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 795 | 0.100 |
Why?
| | Prospective Studies | 3 | 2022 | 6216 | 0.100 |
Why?
| | Risk | 1 | 2014 | 815 | 0.100 |
Why?
| | Angiogenesis Inhibitors | 1 | 2013 | 215 | 0.100 |
Why?
| | Patient Care Team | 1 | 2016 | 517 | 0.100 |
Why?
| | Ligands | 1 | 2013 | 564 | 0.100 |
Why?
| | Neoplasm, Residual | 2 | 2022 | 104 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2199 | 0.090 |
Why?
| | Transcriptome | 1 | 2015 | 727 | 0.090 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2013 | 398 | 0.090 |
Why?
| | Apoptosis | 3 | 2022 | 2369 | 0.090 |
Why?
| | Cytokines | 2 | 2015 | 1843 | 0.080 |
Why?
| | Patient Satisfaction | 1 | 2013 | 583 | 0.080 |
Why?
| | Neutrophils | 1 | 2015 | 1163 | 0.080 |
Why?
| | Streptococcaceae | 1 | 2009 | 2 | 0.080 |
Why?
| | Clinical Medicine | 1 | 2009 | 19 | 0.080 |
Why?
| | Chemoradiotherapy | 2 | 2023 | 190 | 0.080 |
Why?
| | Myositis | 1 | 2009 | 44 | 0.080 |
Why?
| | Mice | 4 | 2021 | 14916 | 0.080 |
Why?
| | Bortezomib | 1 | 2008 | 41 | 0.080 |
Why?
| | Sulindac | 1 | 2008 | 17 | 0.080 |
Why?
| | Taiwan | 1 | 2008 | 15 | 0.080 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1122 | 0.080 |
Why?
| | Mutation Rate | 2 | 2019 | 26 | 0.080 |
Why?
| | Nausea | 1 | 2008 | 103 | 0.080 |
Why?
| | Maximum Tolerated Dose | 1 | 2008 | 184 | 0.080 |
Why?
| | Neutropenia | 1 | 2008 | 125 | 0.070 |
Why?
| | Immunoenzyme Techniques | 1 | 2008 | 195 | 0.070 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1435 | 0.070 |
Why?
| | Fluphenazine | 1 | 2007 | 5 | 0.070 |
Why?
| | Risperidone | 1 | 2007 | 26 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2010 | 954 | 0.070 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2007 | 41 | 0.070 |
Why?
| | Exons | 1 | 2008 | 303 | 0.070 |
Why?
| | Anemia | 1 | 2008 | 144 | 0.070 |
Why?
| | Fasting | 1 | 2008 | 242 | 0.070 |
Why?
| | Food | 1 | 2008 | 160 | 0.070 |
Why?
| | Gastrectomy | 2 | 2017 | 82 | 0.070 |
Why?
| | Thrombocytopenia | 1 | 2008 | 177 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2017 | 2127 | 0.070 |
Why?
| | Frontal Lobe | 1 | 2007 | 140 | 0.070 |
Why?
| | Propensity Score | 2 | 2017 | 224 | 0.060 |
Why?
| | Adolescent | 3 | 2020 | 17808 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 994 | 0.060 |
Why?
| | Antipsychotic Agents | 1 | 2007 | 184 | 0.060 |
Why?
| | Survival Analysis | 2 | 2017 | 1218 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2010 | 1084 | 0.060 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2022 | 20 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 41 | 0.050 |
Why?
| | Organoplatinum Compounds | 1 | 2022 | 37 | 0.050 |
Why?
| | Endothelial Growth Factors | 1 | 2022 | 50 | 0.050 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 63 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2022 | 12 | 0.050 |
Why?
| | Radioisotopes | 1 | 2022 | 28 | 0.050 |
Why?
| | Receptors, Peptide | 1 | 2022 | 18 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2022 | 115 | 0.050 |
Why?
| | Intestinal Neoplasms | 1 | 2022 | 24 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2022 | 37 | 0.050 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2022 | 63 | 0.050 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2021 | 29 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2022 | 157 | 0.050 |
Why?
| | Europe | 1 | 2022 | 336 | 0.050 |
Why?
| | North America | 1 | 2022 | 257 | 0.050 |
Why?
| | Chimerism | 1 | 2021 | 28 | 0.050 |
Why?
| | Canada | 1 | 2022 | 322 | 0.050 |
Why?
| | Preventive Medicine | 1 | 2021 | 40 | 0.050 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 62 | 0.050 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 79 | 0.050 |
Why?
| | Hyaluronic Acid | 1 | 2022 | 188 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2022 | 258 | 0.050 |
Why?
| | Liquid Biopsy | 1 | 2020 | 6 | 0.050 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2020 | 40 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 320 | 0.040 |
Why?
| | Geography | 1 | 2020 | 180 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 277 | 0.040 |
Why?
| | SEER Program | 1 | 2020 | 196 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2022 | 227 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 561 | 0.040 |
Why?
| | Sulfonamides | 1 | 2022 | 445 | 0.040 |
Why?
| | Spectrophotometry, Infrared | 1 | 2019 | 43 | 0.040 |
Why?
| | District of Columbia | 1 | 2018 | 24 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 102 | 0.040 |
Why?
| | Karnofsky Performance Status | 1 | 2018 | 36 | 0.040 |
Why?
| | Colon | 1 | 2020 | 233 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 503 | 0.040 |
Why?
| | Multimodal Imaging | 1 | 2019 | 88 | 0.040 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 37 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 114 | 0.040 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 130 | 0.040 |
Why?
| | Delphi Technique | 1 | 2018 | 160 | 0.040 |
Why?
| | Genome, Human | 1 | 2019 | 351 | 0.040 |
Why?
| | Half-Life | 1 | 2017 | 141 | 0.040 |
Why?
| | Mice, Nude | 1 | 2019 | 635 | 0.040 |
Why?
| | American Medical Association | 1 | 2017 | 17 | 0.040 |
Why?
| | Genomic Instability | 1 | 2017 | 38 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2017 | 182 | 0.030 |
Why?
| | Needles | 1 | 2016 | 49 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 372 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 244 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 125 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2017 | 161 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2007 | 3031 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2019 | 433 | 0.030 |
Why?
| | Acute Disease | 1 | 2019 | 912 | 0.030 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2017 | 92 | 0.030 |
Why?
| | Retreatment | 1 | 2016 | 67 | 0.030 |
Why?
| | Incidental Findings | 1 | 2016 | 70 | 0.030 |
Why?
| | Platinum | 1 | 2016 | 38 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 372 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 445 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 524 | 0.030 |
Why?
| | Jagged-1 Protein | 1 | 2015 | 23 | 0.030 |
Why?
| | Serrate-Jagged Proteins | 1 | 2015 | 28 | 0.030 |
Why?
| | Gene Frequency | 1 | 2017 | 481 | 0.030 |
Why?
| | Radiography | 2 | 2016 | 811 | 0.030 |
Why?
| | Gene Duplication | 1 | 2015 | 63 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 110 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2022 | 1393 | 0.030 |
Why?
| | Preoperative Care | 1 | 2017 | 317 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2016 | 339 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 2582 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 663 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2015 | 292 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1226 | 0.030 |
Why?
| | Ultraviolet Rays | 1 | 2016 | 366 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 207 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 689 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2021 | 984 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2016 | 399 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2016 | 460 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 4406 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 1843 | 0.030 |
Why?
| | Skin | 1 | 2016 | 659 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4420 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2016 | 2209 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1635 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 4622 | 0.020 |
Why?
| | Lung | 1 | 2023 | 3546 | 0.020 |
Why?
| | Protein Binding | 1 | 2016 | 1896 | 0.020 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2009 | 22 | 0.020 |
Why?
| | Rats | 1 | 2016 | 4943 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2008 | 60 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2008 | 77 | 0.020 |
Why?
| | Reference Standards | 1 | 2008 | 159 | 0.020 |
Why?
| | Quality of Life | 1 | 2018 | 2357 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 4710 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2019 | 1868 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2008 | 149 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2269 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2008 | 472 | 0.020 |
Why?
| | Infusions, Intra-Arterial | 1 | 1986 | 46 | 0.020 |
Why?
| | Hepatic Artery | 1 | 1986 | 48 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 1795 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2008 | 413 | 0.020 |
Why?
| | Reference Values | 1 | 2007 | 742 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2007 | 683 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2007 | 2382 | 0.010 |
Why?
|
|
Lieu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|